Top

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Panelists discuss how the preliminary results from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory multiple myeloma (R/R MM) highlight promising efficacy in triple-class and penta-class refractory patients, potentially reshaping treatment strategies and challenging existing paradigms in managing heavily pretreated myeloma.

Video content above is prompted by the following: IMMagine-1 Phase 2 Study of Anitocabtagene Autoleucel in R/R MM Background & Objective: The iMMagine-1 trial evaluates anitocabtagene autoleucel (anti-BCMA chimeric antigen receptor [CAR] T-cell therapy) in patients with R/R MM. Preliminary results focus on efficacy and safety in heavily pretreated patients, including those refractory to triple-class (proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies) and penta-class therapies. Preliminary Efficacy: Safety Profile: Clinical Implications: These findings highlight anitocabtagene autoleucel as a promising therapeutic option in the evolving R/R MM landscape, warranting continued investigation in larger cohorts.

.